Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines June 2, 2026 8:30 AM EDT
Company Participants
Nivi Nehra – Vice President of Corporate Communications & Investor Relations
Eric Dube – President, CEO & Director
Jula Inrig – Chief Medical Officer
Conference Call Participants
Joseph Schwartz – Leerink Partners LLC, Research Division
Arseniy Shabashvili – Guggenheim Securities, LLC, Research Division
Anupam Rama – JPMorgan Chase & Co, Research Division
Prakhar Agrawal – Cantor Fitzgerald & Co., Research Division
Gavin Clark-Gartner – Evercore ISI Institutional Equities, Research Division
Laura Chico – Wedbush Securities Inc., Research Division
Sadia Rahman – Wells Fargo Securities, LLC, Research Division
Alexander Thompson – Stifel, Nicolaus & Company, Incorporated, Research Division
Farzin Haque – Jefferies LLC, Research Division
Jason Zemansky – BofA Securities, Research Division
Presentation
Operator
Good morning, and welcome to Travere Therapeutics Business Update Call. Today’s call is being recorded. At this time, I would like to turn the conference over to Nivi Nehra, Vice President of Corporate Communications and Investor Relations. Please go ahead, Nivi.
Nivi Nehra
Vice President of Corporate Communications & Investor Relations
Thank you, operator. Good morning, and thank you all for joining us to discuss Travere Therapeutics’ exclusive licensing and collaboration agreement with Everest Medicines. Today’s call will be led by Dr. Eric Dube, our President and Chief Executive Officer. Eric will be joined in the prepared remarks by Dr. Jula Inrig, our Chief Medical Officer. Chris Cline, our Chief Financial Officer, will join us for the Q&A.
Before we begin, I’d like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, performance
